Ypsomed intends to expand the production of pens for injecting insulin at its facility in Solothurn. According to a press release, this decision was made on account of major customers increasing their orders long term. By the end of 2020, 40 new full-time jobs are to be created in project and production operations.
In addition to new jobs, Ypsomed will be shifting 110 roles from the headquarters in Burgdorf to the Solothurn site. This will reportedly above all affect employees in the areas of product management, mechanical, hardware and software development, logistics, regulatory affairs and quality assurance. To accommodate the additional staff, Ypsomed will take several office buildings in Solothurn into use that were previously rented out.
“By using our existing office space in Solothurn, we can facilitate agile teamwork in research and development as well as production management,” commented Simon Michel, CEO of Ypsomed. “Our cross-departmental work processes can therefore be made more efficient and streamlined. This will enable us to secure the growth of our company in the long term.”
At present, Ypsomed reports it has 1,604 employees, of whom 1,089 are in Switzerland and 456 in Solothurn. Over the next three years, the company plans to create 300 new jobs in Switzerland, at both Solothurn and Burgdorf.